M ullerian adenosarcomas of the female genital tract are rare malignancies, originally described in 1974 by Clement and Scully, 1 in the uterus, the most common site of origin, but they may also arise in extrauterine locations including the cervix, ovary, vagina, fallopian tube, and intestinal serosa. Uterine adenosarcomas make up 5% of uterine sarcomas and tend to occur in postmenopausal women but may also be diagnosed in adolescents and young women. 2 They are usually low-grade tumors and are characterized by a benign epithelial component with a malignant mesenchymal component, which is typically a low-grade endometrial stromal sarcoma (ESS) but can also be a high-grade sarcoma occasionally. 3Y6 Tumors that exhibit a high-grade sarcomatous overgrowth have a worse outcome. Adenosarcomas have been described as being midway along the spectrum between benign adenofibromas and carcinosarcomas but are considered to be a tumor of low malignant potential. 3, 4 However, the distinction at the lower end of the spectrum can be problematic. 3 Typically, uterine adenosarcomas are polypoid tumors that arise from the endometrium and can protrude through the cervical os. It may be difficult to make a definitive diagnosis from a small biopsy as the sarcomatous stroma can appear deceptively bland histologically. They generally have a good prognosis with the exception of deeply invasive tumors or those with high-grade sarcomatous overgrowth. Extrauterine adenosarcomas also have a higher risk for recurrence. 3, 4 Clement and Scully 5 initially reported the clinicopathological features and prognosis in 100 patients with uterine adenosarcoma. Recurrent disease developed in 23 cases, and approximately one third of these relapsed 5 or more years after hysterectomy. Recurrent tumor was almost always confined to the vagina, pelvis, or abdomen. Distant metastases occurred in only 2 cases in this series. Risk factors associated with recurrence and metastases include deep myometrial invasion, lymph-vascular space invasion, sarcomatous overgrowth, spread outside the uterus, and the presence of heterologous elements in the primary tumor. 5 In view of their rarity, there have not been any clinical trials in mullerian adenosarcomas and relatively little research. There are numerous small clinicopathological series as well as many case reports and a number of recent excellent reviews by McCluggage 3 , D'Angelo and Prat, 4 and Clement and Scully, 5, 6 which, in addition to a number of other articles and case reports, form the basis of this review.
EPIDEMIOLOGY
A recent population-based study from Norway reported that adenosarcomas account for 5.5% of uterine sarcomas. 2 Extrauterine examples are even more uncommon and have been reported to occur in the ovary, vagina, fallopian tube, and peritoneal sites such as the pouch of Douglas and also the intestinal serosa. 3, 4, 7 Extrauterine adenosarcomas have been reported to arise in association with endometriosis. There have been a number of case reports of adenosarcomas arising in women on tamoxifen 8 or toremifine 9 or with endogenous hyperestrogenism, 10 but apart from these relatively few cases, no specific risk or etiological factors have been reported. They can occur in all age groups but most commonly after menopause. In one of the largest series, the peak incidence was in the eighth decade with only 38% occurring in younger than 50 years. 5 However, in a recent large Surveillance , Epidemiology And End Results Program (SEER) registry-based study that included 544 patients with uterine adenosarcomas collected for 18 years, most patients were diagnosed between the age of 40 and 65 years with 38% older than 65 and 10% younger than 40.
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CLINICAL PRESENTATION
Typically, uterine adenosarcomas grow as a polypoid mass within the endometrial cavity. 3Y6 The most common symptom of uterine adenosarcomas is vaginal bleeding, but some patients present with pelvic pain, vaginal discharge, or symptoms related to uterine enlargement. On examination, patients often have a polypoid mass protruding through a dilated cervical os, which may be confused with benign cervical or endometrial polyps, but they may also have an enlarged uterus. 3Y6 There have been a few case reports of magnetic resonance imaging, which typically shows an endometrial cavity distended by a polypoid mass that has solid components with high signal intensity compared with the myometrium on both sequences, small cystic areas, and similar enhancement to the myometrium after administration of gadolinium.
12 Approximately 20% to 30% of adenosarcomas arise in extrauterine sites including the vagina, fallopian tube, pouch of Douglas, and ovary, and these have no specific clinical features and are diagnosed pathologically. 3Y6,13 In the largest series of ovarian adenosarcomas, the tumors were unilateral and ranged in size from 5 to 50 cm, and abdominal discomfort was the usual presenting symptom. 14 
PATHOLOGY
The uterus typically contains a polypoid lobulated mass, which may project through the cervical os. The tumors range in size from 1 to 17 cm. 3 
Microscopic
Adenosarcoma is characterized by a biphasic cellular differentiationVthe essential features include a benignappearing epithelial component and a (definitionally) malignant mesenchymal component.
3Y6 At low power, the tumor may resemble a phyllodes tumor of the breast. 3 The epithelial component is usually endometrioid in type. 3 The malignant stromal component is typically low grade. The World Health Organization requires the stromal mitotic rate to be in excess of 1 per 10 high power fields for a diagnosis of adenosarcoma, whereas others suggest a higher cutoff of 4 per 10 high power fields. 3 However, McCluggage 3 suggests that, given the problem with counting mitoses, if the characteristic leaflike architecture is present with periglandular cuffing, then a diagnosis can be made even in the absence of mitotic figures. The nuances in pathological diagnosis are well described in the review articles by McCluggage 3 and D'Angelo and Prat. 4 Most adenosarcomas contain only homologous mesenchymal elements with the most common stromal element resembling ESS. 3 Undifferentiated sarcoma is relatively uncommon. Approximately 25% of adenosarcomas have heterologous components with rhabdomyoblasts predominating, but a variety of other sarcomatous subtypes have been reported including chondrosarcoma, liposarcoma, and sex cord-stromal tumors. 3 Adenosarcomas with more than 25% of the tumor composed of pure high-grade sarcoma are designated as adenosarcomas with sarcomatous overgrowth. They typically are composed of poorly differentiated sarcoma and may be associated with deep myometrial and vascular invasion. 
IMMUNOHISTOCHEMISTRY
In most adenosarcomas with a low-grade stromal component, the stromal element expresses estrogen receptor, progesterone receptor, CD10, and WT1 and is negative for P53, which is similar to the immunophenotype of ESSs. 3, 15, 16 The CD10 is the common acute lymphoblastic leukemia antigen and is a membrane glycoprotein that functions as a cell surface enzyme, which reduces cellular response to peptide hormones, and is a specific marker for ESSs, which is commonly the stromal component in adenosarcomas. 16 Amant et al 16 reported that 90% (18/20) of uterine adenosarcomas were CD10 positive, whereas 63% (5/8) adenosarcomas with sarcomatous overgrowth were CD10 positive. The epithelial component was negative in all cases. The CD10 is diagnostically a useful marker for endometrial stromal tumors and can also be used in establishing the diagnosis of uterine adenosarcomas. 16 In high-grade sarcomas, the immunphenotype corresponds to the specific sarcomatous subtype present such as desmin, myogenin, and myoD1 reactivity in rhabdomyoblasts. 3 
DIFFERENTIAL DIAGNOSES
Most important is the threshold differentiation between adenosarcoma and adenofibroma. 3, 17, 18 Prat believes that some tumors classified as adenofibromas on the basis of a low mitotic count and lack of nuclear atypia are extremely welldifferentiated adenosarcomas. 18 McCluggage 3 also suggests that adenofibromas and adenosarcomas should be combined into a single neoplastic category and renamed as low-grade mixed Mullerian tumor to reflect that they form part of a spectrum with the risk for recurrence and metastases being unpredictable and often impossible for the pathologist to make on morphological grounds alone. Even a confident histological diagnosis of adenofibroma should alert the physician to the possibility of adenosarcoma with institution of a regime of close clinical follow-up. Early clinical recurrence of the polyp should be regarded with suspicion. Other differential diagnoses include carcinosarcomas, benign endometrial polyps, adenomyomatous polyps, ESS with focal endometrial glands, and occasionally, even cervical embryonal rhabdomysosarcomas.
3,4
MOLECULAR PATHOLOGY
There do not seem to have been any published reports specifically on mullerian adenosarcomas, although they have been included in some studies. Given that most tumors have ESS as the malignant component, it is possible that they will share the molecular features with de novo ESSs. 19 Amant et al has written a Gynecologic Cancer Intergroup review on ESSs, and the molecular pathology is described in detail. Briefly, ESSs represent a genetically heterogeneous group of tumors, many of which may arise through distinctive molecular genetic pathways, through gene rearrangements, which most frequently are a JAZF1-SUZ12 rearrangement. 
TREATMENT
The treatment of uterine adenosarcomas is a hysterectomy and bilateral salpingo-oophorectomy. Ovarian metastases seem to be very uncommon, and a good case can be made for not removing the ovaries in premenopausal women. There have been individual case reports of more conservative surgery with hysterectomy alone with ovarian preservation in premenopausal women, 25, 26 and the treatment decisions need to be individualized based on age and clinicopathological parameters. The incidence of lymph node involvement is reported to be low in stage 1 uterine adenosarcomas and was only 3% in the SEER study, 11 indicating that lymphadenectomy is not required for most patients. The role of adjuvant irradiation, chemotherapy, or hormonal therapy is unclear and unlikely will ever be addressed in a clinical trial as they are so uncommon. Given that most uterine adenosarcomas have a low-grade ESS component, the principles of management of these tumors should follow the guidelines for ESS as described by Amant et al. Arguably, these tumors should be included in studies of ESS but stratified as adenosarcoma/ ESS. In a historical series of 100 patients, recurrent tumor occurred in 23 patients at a mean interval after diagnosis of 3.4 years (range, 0.5Y9.5 years), with most recurrences being local recurrences. 5 The only factor associated with local recurrence was the presence of myometrial invasion, which raises the question regarding the role of adjuvant pelvic radiation or brachytherapy in these patients. It is even more difficult to make recommendations on the management of extrauterine adenosarcomas as they are so rare and management should be based on surgical principles. It is unlikely that the diagnosis would be known before surgery in most of these patients and would only be made on the final histopathology.
PROGNOSIS
A number of series have reported that stage, depth of tumor invasion, grade, mitotic index, presence of heterologous elements, and sarcomatous overgrowth are all of prognostic importance. 3Y6,11 Of these, depth of myometrial invasion and extrauterine spread are reported to be the most important. Zaloudek and Norris 17 found that deep myometrial invasion was the only factor associated with recurrence in their series. However, most adenosarcomas are confined to the endometrium at diagnosis. In a series of 100 patients reported by Clement and Scully, 5 myometrial invasion was present in 15%, and deep invasion was present in 4%.The largest study to date is based on the SEER registry and includes 544 patients with uterine adenosarcoma and almost 5000 patients with uterine carcinosarcoma treated for 18 years, between the years 1998 and 2006.
11 Lymphadenectomy was performed in 262 patients (48%), and nodal metastases were reported in 3% of patients. 11 Most women had stage I tumors, and only 11% were at stages 3 or 4 at diagnosis. Among the women with stage I disease where depth of invasion was known, 41% had myometrial invasion including 6% into the outer half. The 5-year survival for stage 1A uterine adenosarcoma was 84% (95% confidence interval, 77%Y89%) compared with 62% for carcinosarcoma. 11 The 5-year survival rates for all substages of adenosarcomas were 69%, IB; 63%, IC; 69%, II; 48%, III; and 15%, IV. 11 The corresponding survival figures in patients with carcinosarcomas at all stages were much lower, as one would expect. They also found that, in addition to pathological factors, age and race were also associated with survival with a worse prognosis for women older than 60 years (hazard ratio, 2.91) compared with women younger than 40 years.
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The mortality was also higher in African American women. The incidence of sarcomatous overgrowth was not captured in the SEER data but, in other ,studies has been associated with a poor prognosis and high risk for relapse and death. For example, in a small Gynecological Oncology Group study of 31 patients with adenosarcoma, the recurrence rate of adenosarcomas with overgrowth was 44% compared with 14% without overgrowth. 27 
METASTATIC DISEASE
The management of patients with metastatic adenosarcoma depends on multiple factors, including the age and comorbidities of the patient, the site/s of recurrence, time to recurrence, the number of metastases, and the sarcomatous subtype. Given that ESS is the most common subtype, the treatment options would be similar to the management of patients with metastatic ESS with hormonal therapy including progestagens and/ aromatase inhibitors, although there are no published reports on response to hormonal therapies in adenosarcomas with an ESS component. The management of patients with high-grade metastatic adenosarcomas is similar to the management of patients with metastatic high-grade sarcomas. These are all so rare, and the literature contains only a number of individual case reports of responses to trabectadin, liposomal doxorubicin, anthracyclines, and ifosfamide. 28, 29 It is likely that there may be reporting bias as the few reports of chemotherapy in metastatic high-grade adenosarcoma suggest high response rates, very durable remissions, and even apparent cures. In contrast, one of the larger case series describing the treatment of 13 patients with recurrent adenosarcomas has been recently reported. 30 Six patients had disease confined to the abdomen or pelvis, had surgical resection at the time of recurrence, and had a time-tosecond recurrence of 29.7 versus 12.7 months for patients treated with nonsurgical therapy alone, suggesting that secondary cytoreduction may be of benefit in selected patients. Eleven of the 13 patients with measureable disease received chemotherapy, hormonal therapy, or radiation. Only 1 of the 5 patients had a durable response to hormonal therapy. There were partial responses of short duration observed with ifosfamide and doxorubicin in 2 patients with a high-grade sarcomatous component and a brief response to gemcitabine and docetaxel in 1 patient. 30 It seems unlikely that there is anything intrinsically different between high-grade sarcomas arising in adenosarcomas and their histological counterparts that arise de novo and a similar approach to management as in other sarcomas is reasonable.
PERSPECTIVE
Adenosarcomas are rare tumors and comprise only 5% of uterine sarcomas, which are also uncommon in their own right and have been difficult to study in clinical trials. It is unlikely that clinical trials can be carried out in patients with these tumors as they are so uncommon. However, patients with adenosarcomas with ESS could be included in studies of ESS, but they should be stratified separately as it is possible that they may be different to de novo ESS. It is not possible to make any evidence-based recommendations on the treatment of metastatic disease given their rarity, but 1 approach is to register all these patients prospectively in a rare gynecological tumor register to collect data prospectively. The relatively few case reports indicate high responses and durable remissions with hormonal therapy in some patients. This may simply reflect reporting bias, and a prospective registry would eventually help answer questions such as this and also improve our approach to the management of patients with these rare tumors.
